title: Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial.
abstract: The aim of this study was to report long-term results of patients with locally advanced rectal cancer treated by neoadjuvant chemoradiotherapy with fluorouracil, leucovorin, and oxaliplatin. From February 2002 to November 2006, a total of 58 patients with locally advanced rectal cancer were recruited. Secondary endpoints included the cumulative incidence of local and distant recurrences, disease-free survival, and overall survival. The median follow-up time was 138 months (109-151 months). The cumulative incidence of local recurrence at 10 years was 12.1%. The cumulative incidence of distant recurrence at 10 years was 53.4%. The overall survival in the intention-to-treat population was 39.5% at 10 years. Disease-free survival in the intention-to-treat population was 41.8% at 10 years. Univariate analysis revealed that pathologic complete response was associated with local recurrence, distant recurrence, disease-free survival, and overall survival (p < .05). Distant recurrence remains the predominant pattern of failure for patients with locally advanced rectal cancer after preoperative chemoradiotherapy and total mesorectal excision. Pathologic complete response is an independent prognostic factor for locally advanced rectal cancer after preoperative chemoradiotherapy.
authors.affiliation: Department of Radiation Oncology, Zhejiang Cancer Hospital, No. 38, Guangji Road, Hangzhou, 310022, China.
authors.forename: Luying
authors.initials: L
authors.lastname: Liu
authors.forename: Caineng
authors.initials: C
authors.lastname: Cao
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhu
authors.forename: Dechuan
authors.initials: D
authors.lastname: Li
authors.forename: Haiyang
authors.initials: H
authors.lastname: Feng
authors.forename: Jialin
authors.initials: J
authors.lastname: Luo
authors.forename: Zhongzhu
authors.initials: Z
authors.lastname: Tang
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Ke
authors.initials: K
authors.lastname: Lu
authors.forename: Haixing
authors.initials: H
authors.lastname: Ju
authors.forename: Na
authors.initials: N
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011300:Preoperative Care; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil